Clinical trial
Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia
NCT00003746 · Swiss Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00003746 |
|---|---|
| Title | Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia |
| Official title | Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine (CDA) in Patients With Hairy Cell Leukemia |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | 2-chlorodeoxyadenosine (CDA) daily, 2-chlorodeoxyadenosine weekly |
| Enrollment | 100 |
| Start date | Sep 1, 1998 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2010 |
| First posted | Jan 27, 2003 |
| Last update posted | May 15, 2012 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: